Company / Cash & Equivalents
Penumbra, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$186.9M
FY2025
5-year range
$59.4M / $324.4M
FY2021-FY2025
Trend
-42.4%
vs FY2024
Sector context
#86 of 148
Health Care
What the data says
At $187M, Penumbra, Inc.'s cash & equivalents ranks #86 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $13M in FY2016 to $324M in FY2024.
Based on SEC 10-K filings.
$187M in FY2025 with a 5-year CAGR of +21.8%.
Improved from $167M to $187M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +38.8%
- 5-Year CAGR
- +21.8%
- 10-Year CAGR
- -
Sector benchmark
#86 of 148 in Health CareTop 58% of 148This company $186.9M Sector average $1.2B
▼
-84.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 42.4% year-over-year.
- Ranks #86 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.11 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $186.9M | -42.4% |
| FY2024 | $324.4M | +93.7% |
| FY2023 | $167.5M | +139.8% |
| FY2022 | $69.9M | +17.6% |
| FY2021 | $59.4M | -14.8% |
| FY2020 | $69.7M | -4.3% |
| FY2019 | $72.8M | +43.7% |
| FY2018 | $50.6M | +159.1% |
| FY2017 | $19.5M | +47.7% |
| FY2016 | $13.2M | -32.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026